Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study
Go back to Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study| Pfizer Inc. (NYSE: PFE) | Delayed: 27.66 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.66 | 52 Week High | $37.39 | |||
| Open | $27.66 | 52 Week Low | $28.25 | |||
| Day High | $27.66 | P/E | 16.76 | |||
| Day Low | $27.66 | EPS | $1.65 | |||
| Volume | 50,796 | |||||
